Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX Announces Filing of FDA pre-IND Meeting Request Letter

XORTX Announces Filing of FDA pre-IND Meeting Request Letter
XORTX Announces Filing of FDA pre-IND Meeting Request Letter

Press Releases

  • XORTX Therapeutics Announces Share Consolidation September 20, 2021
  • XORTX Therapeutics Reports Special Meeting Results September 2, 2021
  • XORTX Announces Grant of European Patent September 1, 2021
  • XORTX Announces New Clinical Advisory Board Member August 31, 2021
  • XORTX Therapeutics Calls Special Meeting of Shareholders August 13, 2021
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress